Etentamig vs YKST02

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Multiple Myeloma

Shared mechanism: BCMA x CD3 · full Multiple Myeloma pipeline

Etentamig

Developed by AbbVie

Phase 3 in Multiple Myelomabispecific antibody
Partial signal

NCT06158841 · Phase 3 · active, not recruiting

This was a randomized, open-label Phase 3 trial with 421 participants. Its primary endpoint was met according to the sponsor's announcement of 2026-09-03. An open-label trial is never graded strong; with a sponsor-reported result, the grade is moderate.

Next expected readout: February 2027 · NCT06223516 (registry estimate)

Reported efficacy

Progression Free Survival (PFS) (Up to Approximately 5 Years); Objective Response Rate (ORR) (Up to Approximately 5 Years): Dual primary endpoints met: objective response rate and progression-free survival vs standard available therapies (PFS HR 0.40, P<0.0001) (AbbVie, 2026-09-03). (met)

Result source: NCT06158841

YKST02

Developed by EXCYTE (Beijing) Pharmaceutical Technology Development Co., Ltd.

Phase 2 in Multiple Myelomabispecific antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2026 · NCT06574568 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Multiple Myeloma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointEtentamigYKST02
PFS, median—Trial running · NCT07095452—Not reported
OS, median—Trial running · NCT07095452—Not reported
ORR—Trial running · NCT07095452—Not reported
VGPR or better—Trial running · NCT07095452—Not reported
MRD negativity—Trial running · NCT07095452—Not reported

PFS, median

Etentamig
—Trial running · NCT07095452
YKST02
—Not reported

OS, median

Etentamig
—Trial running · NCT07095452
YKST02
—Not reported

ORR

Etentamig
—Trial running · NCT07095452
YKST02
—Not reported

VGPR or better

Etentamig
—Trial running · NCT07095452
YKST02
—Not reported

MRD negativity

Etentamig
—Trial running · NCT07095452
YKST02
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

YKST02: no structured comparison results are available for Multiple Myeloma.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Etentamig
Dual primary endpoints met: objective response rate and progression-free survival vs standard available therapies (PFS HR 0.40, P<0.0001) (AbbVie, 2026-09-03). NCT06158841 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Etentamig's landscape · YKST02's landscape